T–CELL VACCINE PREPARATION FOR MULTIPLE SCLEROSIS TREATMENT

Abstract. A two–stage technology of preparation of T–cell vaccine designated for multiple sclerosis treatment is described. At the first stage myelin–specific lymphocytes undergoe antigen–dependent cultural selection, whereas at the second stage they are grown by means of non–specific stimulation. T...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: I. P. Ivanova, V. I. Seledzov, N. V. Banul, D. M. Samarin, G. V. Seledzova, I. V. Savkin, V. S. Shyrinsky, N. V. Pronkina, V. A. Kozlov
Formato: article
Lenguaje:RU
Publicado: SPb RAACI 2014
Materias:
Acceso en línea:https://doaj.org/article/156eef87702e4a15b3cdf661fd2847b3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract. A two–stage technology of preparation of T–cell vaccine designated for multiple sclerosis treatment is described. At the first stage myelin–specific lymphocytes undergoe antigen–dependent cultural selection, whereas at the second stage they are grown by means of non–specific stimulation. The vaccine prepared in this way was found to induce specific anti–idiotypic immune response, directed against myelin–reactive T–lymphocytes. The results of 1–year follow–up of 18 vaccinated patients with a cerebral–spinal type of multiple sclerosis indicated the absence of side effects of T–cell vaccination, and suggest the possibility of effective application of this treatment within early stages of disease. (Med. Immunol., 2005, vol.7, № 1, pp 27532)